I think the results are great. Less pain for the entire study population. Less opioid use ( that includes people with both short and long term history of pain). The only negative was that there wasn't sufficient improvement in function for long term sufferers to meet statistical significance for the composite measure for the entire study population.
The results show great benefit for those with both short and long term history of back pain. They show fantastic benefits for those with a shorter history of pain.
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-342
-
- There are more pages in this discussion • 762 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
-0.010(0.76%) |
Mkt cap ! $1.501B | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.33 | $1.28 | $1.183M | 910.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 20024 | $1.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.32 | 27007 | 8 |
View Market Depth
| Last trade - 14.05pm 01/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |